Skip to main content

Risankizumab Side Effects

Medically reviewed by Philip Thornton, DipPharm. Last updated on Jan 10, 2025.

Applies to risankizumab: parenteral injection for iv infusion, parenteral injection for sub-q use.

Side effects include:

Adverse reactions (≥1%) in patients with plaque psoriasis and psoriatic arthritis: upper respiratory infection, headache, fatigue, injection site reaction, tinea infection.

Adverse reactions (>3%) in patients receiving induction treatment for Crohn disease: upper respiratory infection, headache, arthralgia.

Adverse reactions (>3%) in patients receiving maintenance treatment for Crohn disease: arthralgia, injection site reaction, abdominal pain, anemia, pyrexia, back pain, arthropathy, urinary tract infection.

Adverse reactions (≥3%) in patients receiving induction treatment for ulcerative colitis: arthralgia.

Adverse reactions (≥3%) in patients receiving maintenance treatment for ulcerative colitis: arthralgia, pyrexia, injection site reactions, rash.

For healthcare professionals

Applies to risankizumab: intravenous solution, subcutaneous kit, subcutaneous solution.

Gastrointestinal adverse events

Dermatologic

Postmarketing: Eczema, rash[Ref]

Hematologic

Hypersensitivity

Hypersensitivity

Immunologic

Local

Musculoskeletal

Nervous system

Other

Respiratory

See also:

References

1. (2024) "Product Information. Skyrizi (risankizumab)." AbbVie US LLC, SUPPL-32

2. (2019) "Product Information. Skyrizi (risankizumab)." AbbVie US LLC

Frequently asked questions

Further information

Risankizumab side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.